Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

邁博藥業

Mabpharm Limited

迈博药业有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2181)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON FRIDAY, JUNE 26, 2026

References are made to the Notice (the "**Notice**") of the annual general meeting (the "**AGM**") and the circular (the "**Circular**") of Mabpharm Limited (the "**Company**") both dated April 27, 2026. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS

At the AGM of the Company held on Friday, June 26, 2026, all the proposed resolutions (the "**Proposed Resolutions**") as set out in the Notice were duly passed by the Shareholders as ordinary resolutions or special resolution (as the case may be) by way of poll.

As at the date of the AGM, the total number of issued Shares was 4,124,080,000, which was the total number of shares entitling the Shareholders to attend and vote for or against the Proposed Resolutions at the AGM. There was no restrictions on any Shareholders to cast votes on any of the Proposed Resolutions at the AGM. As at the date of the AGM, the Company did not hold any treasury shares and there was no shares repurchased by the Company which were pending cancellation.

None of the Shareholders were required under the Listing Rules to abstain from voting at the AGM. There were no shares entitling the Shareholders to attend and abstain from voting in favor of any of the Proposed Resolutions at the AGM as set out in Rule 13.40 of the Listing Rules. None of the Shareholders have indicated in the Circular that they intended to vote against or to abstain from voting on any Proposed Resolutions at the AGM. No Shares were actually voted but excluded from calculating the poll results.

The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. All directors of the Company attended the AGM in person or by electronic means. The board of the Company (the "**Board**") is pleased to announce the poll results in respect of all the Proposed Resolutions at the AGM as follows:

Ordinary Resolutions		**Number of Votes (%)**	
		For	**Against**
1.	To receive and consider the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended December 31, 2025.	2,359,000,000 (100%)	0 (0%)
2(a).	To re-elect Mr. Li Yunfeng as executive director.	2,359,000,000 (100%)	0 (0%)
2(b).	To re-elect Mr. Tao Jing as executive director.	2,359,000,000 (100%)	0 (0%)
2(c).	To re-elect Dr. Hou Sheng as executive director.	2,359,000,000 (100%)	0 (0%)
2(d).	To re-elect Mr. Leung, Louis Ho Ming as independent non-executive director.	2,359,000,000 (100%)	0 (0%)
2(e).	To authorize the board of directors to fix directors' remuneration.	2,359,000,000 (100%)	0 (0%)
3.	To re-appoint Ernst & Young as auditors and to authorize the board of directors to fix their remuneration.	2,359,000,000 (100%)	0 (0%)
4.	To grant a general mandate to the directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company as at the date of passing of this resolution.	2,359,000,000 (100%)	0 (0%)
5.	To grant a general mandate to the directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of passing of this resolution.	2,359,000,000 (100%)	0 (0%)
6.	To extend the general mandate granted to the directors to issue, allot and deal with additional shares in the capital of the Company under resolution no. 5 above by the aggregate number of the shares repurchased by the Company pursuant to the mandate under resolution no. 4 above.	2,359,000,000 (100%)	0 (0%)

Special Resolution		Number of Votes (%)	
		For	Against
7.	The amended and restated memorandum and articles of association of the Company (the "**Amended M&A**") be approved and adopted and any director of the Company be authorized to do all such acts and things necessary to implement the adoption of the Amended M&A.	2,359,000,000 (100%)	0 (0%)

As more than 50% of the votes were cast in favour of each of the above ordinary resolutions numbered 1 to 6, all of them were duly passed as ordinary resolutions of the Company at the AGM.

As more than 75% of the votes were cast in favur of resolution numbered 7, resolution numbered 7 was duly passed as special resolution of the Company at the AGM.

AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION

The Board hereby announces that the resolution on the proposed amendments to the existing memorandum and articles of association of the Company has been duly passed as a special resolution at the AGM. For details of the proposed amendments, please refer to Appendix III to the Circular.

The third amended and restated memorandum and articles of association of the Company will take effect from June 26, 2026, the full text of which is available on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.mabpharm.cn).

By order of the Board
Mabpharm Limited
Jiao Shuge
Chairman

Shanghai, the PRC
June 26, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu as executive Directors; Mr. Jiao Shuge and Mr. Cen Jialin as non-executive Directors; and Dr. Zhang Yanyun, Mr. Guo Liangzhong, Mr. Leung, Louis Ho Ming and Dr. Tao Qian as independent non-executive Directors.